# EDGAR Filing Document

**Accession Number:** 0001479290
**File Stem:** 0001479290-23-000052
**Filing Date:** 2023-3
**Character Count:** 3466
**Document Hash:** 6192b8436c3368835e1ffb81876d662d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001479290-23-000052.hdr.sgml**: 20230331

**ACCESSION NUMBER**: 0001479290-23-000052

**CONFORMED SUBMISSION TYPE**: DEFA14A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20230331

**DATE AS OF CHANGE**: 20230331

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Revance Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001479290
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 770551645
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** DEFA14A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36297
- **FILM NUMBER:** 23787658

**BUSINESS ADDRESS:**
- **STREET 1:** 1222 DEMONBREUN STREET
- **STREET 2:** SUITE 2000
- **CITY:** NASHVILLE
- **STATE:** TN
- **ZIP:** 37203
- **BUSINESS PHONE:** 6157247755

**MAIL ADDRESS:**
- **STREET 1:** 1222 DEMONBREUN STREET
- **STREET 2:** SUITE 2000
- **CITY:** NASHVILLE
- **STATE:** TN
- **ZIP:** 37203

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**SCHEDULE 14A**

**Proxy Statement Pursuant to Section 14(a) of the** 

**Securities Exchange Act of 1934** 

**(Amendment No.)** 

Filed by the Registrant 🗷

Filed by a Party other than the Registrant ◻

Check the appropriate box:

---

| | |
|:---|:---|
| ◻ | Preliminary Proxy Statement  |
| ◻ | **Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))** |
| ◻ | Definitive Proxy Statement |
| 🗷 | Definitive Additional Materials |
| ◻ | Soliciting Material Pursuant to § 240.14a-12 |
| **Revance Therapeutics, Inc.** | **Revance Therapeutics, Inc.** |
| (Name of Registrant as Specified in its Charter) | (Name of Registrant as Specified in its Charter) |
| (Name of Person(s) Filing Proxy Statement, if other than the Registrant) | (Name of Person(s) Filing Proxy Statement, if other than the Registrant) |
| Payment of Filing Fee (Check all boxes that apply): | Payment of Filing Fee (Check all boxes that apply): |
| 🗷 | No fee required. |
| ◻ | Fee paid previously with preliminary materials. |
| ◻ | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 |

---

------

**SUPPLEMENT TO**

**2023 NOTICE OF ANNUAL MEETING AND PROXY STATEMENT**

**DATED MARCH 23, 2023**

**FOR THE ANNUAL MEETING OF STOCKHOLDERS**

**TO BE HELD ON MAY 3, 2023**

This Supplement provides updated information with respect to the 2023 Annual Meeting of Stockholders (the "Annual Meeting") of Revance Therapeutics, Inc. ("Revance") to be held on May 3, 2023.

On March 23, 2023, Revance commenced distribution of the Notice of Annual Meeting and Proxy Statement (the "Proxy Statement") for the Annual Meeting and notice of availability of the Proxy Statement. This Supplement should be read in conjunction with the Proxy Statement.

This Supplement is being filed to correct the following information in the Proxy Statement. On pages 1 and 5, the number of shares of common stock outstanding and entitled to vote on the record date is corrected from 82,800,000 to 83,850,063, and on page 5, the number of holders that must be present in person, by remote communication or represented by proxy at the meeting to have a quorum is corrected from 41,400,000 to 41,925,032.

Information on how to vote your shares, or change or revoke your prior vote or voting instruction, is available in the Proxy Statement.

<br>